Adjuvant Systems for Vaccines

Adjuvant Systems for Vaccines
Product Description

We enable next-generation vaccine development through a diverse portfolio of world-leading vaccine adjuvants, immunomodulators and adjuvant formulations.

We passionately develop new adjuvant technologies and partner to develop the vaccines of tomorrow.

Our extensive expertise in immunology and formulation of adjuvant systems, proves quality and support through vaccine research and development.

Our diverse and strong portfolio with mineral adjuvants, saponins, glycolipids and nanoparticulate delivery systems such as liposomes, enables vaccine development against a wide range of bacterial and viral pathogens.

We are commited to the highest production standards and have vast experience in cGMP manufacturing.

Please contact us via our exhibitor profile, or visit us at stand 80G90 to speak directly to our experts.

Croda Europe Limited

  • GB
  • 2015
    On CPHI since
  • 2
  • 1000 - 4999
Company types
Primary activities
Excipients Manufacturer

Croda Europe Limited

  • GB
  • 2015
    On CPHI since
  • 2
  • 1000 - 4999
Company types
Primary activities
Excipients Manufacturer

More Products from Croda Europe Limited (24)

  • Excipient: Super Refined™ DEGEE

    Product Excipient: Super Refined™ DEGEE

    Super Refined DEGEE is ideal for use in topical and transdermal applications to enhance the permeation of poorly water-soluble API’s through various layers of the skin, thereby improving drug delivery. It can also be used as a co-solvent in self-emulsifying drug delivery systems (SEDDS), or self-microe...
  • Excipient: Super Refined™ P35 Caster Oil

    Product Excipient: Super Refined™ P35 Caster Oil

    Super Refined P35 Castor Oil is a castor oil derivative, resulting from the reaction of glycerol ricinoleate and 35 mols of ethylene oxide. This product is a liquid nonionic solubiliser and emulsifier, characteristic of a slightly yellow hue, and is intended for use in parenteral, ophthalmic, oral, and...
  • Vaccine Adjuvant: Quil-A™

    Product Vaccine Adjuvant: Quil-A™

    • Quil-A is a highly purified and concentrated saponin adjuvant purified from bark extract of the Quillaja saponaria Molina tree which has been specifically developed for use as an adjuvant in vaccines • Quil-A saponin was originally purified and characterised by Dr. Pharm • Kristian Dalsgaard in 1...
  • Cholesterol

    Product Cholesterol

    W/O emulsifier, emulsion stabiliser and moisturiser with skin conditioning and barrier repair benefits. High purity grade also available. Recommended topical usage levels of 0.5-5%. Cholesterol in the free and combined state is the most widely occurring sterol in animal tissue. It is an essential compound ...
  • Crodafos™ CES pharma

    Product Crodafos™ CES pharma

    Phosphate-based emulsifying and conditioning wax that produces stable thixotropic O/W emulsions, allowing rapid active release and localised delivery of active to the skin. The formation of lamellar liquid crystal oleosomes mean that Crodafos CES-based emulsions offer greater versatility compared to more c...
  • Super Refined™ DMI

    Product Super Refined™ DMI

    Super Refined DMI is a highly purified solubiliser, epidermal penetration enhancer and spreading agent. Applications include topical anti-inflammatory drug delivery, scalp treatments and anti-acne treatments.
  • Excipients for Consumer Health

    Product Excipients for Consumer Health

    Croda Pharma's Consumer Health offering combines our technical expertise with regulatory knowledge to help our customers market innovative products with consumer relevant claims, alongside supporting formulation development challenges within the Consumer Health market.
    Our excipient solutions support ...
  • Nucleic Acid Delivery for Vaccines and Next-Gen Therapeutics

    Product Nucleic Acid Delivery for Vaccines and Next-Gen Therapeutics

    Avanti Polar Lipids, part of Croda Pharma, develops innovative lipids of unparalleled purity to solve the stability and delivery issues associated with mRNA for use in vaccines and next-generation therapeutics.
    We develop and manufacture highly specialised lipids used in Lipid Nanoparticle (LNP) deliv...
  • ALC-0159

    Product ALC-0159

    ALC-0159 is a polyethylene glycol (PEG)-lipid conjugate also called a PEGylated lipid.

    ALC-0159 is a lipid excipient that can be used to form lipid nanoparticles (LNPs). 
  • ALC-0315

    Product ALC-0315

    ALC-0315 is an ionizable cationic lipid used in combination with other lipids to form lipid nanoparticles (LNPs). 
  • Cationic Adjuvant Formulation CAF®

    Product Cationic Adjuvant Formulation CAF®

    Croda Pharma continuously increases its offering in innovative vaccine adjuvant systems. The strategic collaboration with SSI (Statens Serum Institut, leading Danish governmental life-science research institute) enables us to offer an even more diverse adjuvant portfolio. 

    The CAF® t...

    Product ENT-DSPC

    Ent-DSPC/Ent-2,3-Distearoyl-sn-Glycero-1-Phosphocholine is an enantiomer of the compound DSPC/2,3-distearoyl-sn-glycero-1-phosphocholine.

    Enantiomers are also known as optical isomers, optical antipodes, or just antipodes. They are pairs of non-superimposable mirror forms of one another. Enantio...

Croda Europe Limited resources (14)

  • Sponsored Content Croda: Solutions for Your High Value Drug Products

    Formulating a drug for parenteral delivery comes with its fair set of challenges. Aside from a high level of sensitivity to external factors like light and heat exposure, these large and complex drugs are prone to degradation when exposed to various chemical species.
  • Brochure Addressing the challenges of vaccine formulation

    To this day, our focus has been to successfully develop, manufacture and market high-quality adjuvants for our pharmaceutical customers. This heritage makes our vaccine adjuvants unique in the industry. A heritage we are proud of. 

    Our industry-leading, Alhydrogel®, Adju-Phos® and Quil-A® are widely recognised in the vaccine industry for their unmatched track record when it comes to a proven history of safe and effective use.
  • Sponsored Content Avanti & Croda-Denmark: Advancing Vaccine Adjuvant Research

    Adjuvants. You’ve seen them on our website. You’ve seen them featured in our blog articles. Now we want to show you how Avanti’ & Croda-Denmark can enhance your vaccine adjuvant research!

    Keep reading to learn more!

  • Brochure Avanti cGMP Manufactured Lipids

    For over 40 years Avanti has provided API (Active Pharmaceutical Ingredient) Technology Development for Pharmaceutical and Biotechnology companies. Our unique reputation for quality in the development of pre-clinical and clinical candidates is well established. Our full range of services include process chemistry, scale-up manufacturing, supply chain management with analytical and regulatory requirements. Avanti’s experienced staff of chemists and lipid analysts are ready to meet your development needs with pre-clinical through phase III and commercial launch.
  • News Top 5 Industry Content Reads on CPHI Online This Month

    If you’re looking for news, product information and market trends from leading pharma companies, the Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

  • Brochure Croda Mill Hall press release

    Croda International Plc, the company that uses smart science to create high performance ingredients and technologies that improve lives, is excited to announce the expansion of its Mill Hall high purity excipients facility. This investment confirms Croda’s commitment to building its Life Sciences business and developing innovative pharmaceutical excipients, reinforcing Croda’s Purpose to use Smart science to improve lives™. With this latest Mill Hall expansion, Croda continues their ambitious target to become People Positive by 2030 by contributing to the successful development of 25% of WHO-listed pipeline vaccines.

    To find out more, please visit:
  • News Construction underway on new Croda North American HQ and Innovation Centre

    The facility will support the company'a goal of being climate, land and people positive by 2030.
  • Technical Data Polysorbates for Biopharma

    Super Refined™ Polysorbates for Biopharma applications.

    This document is relevant to the following market areas

    Health Care - DermaHealth Care - Pharma
    Health Care - Nutra
    Health Care - Animal Health

    This document is attached to the following products

    Super Refined™ Polysorbate 80
  • News Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids

    The transaction will more than double Croda’s R&D capability in drug delivery.
  • Technical Data Pharmaceutical excipients for ophthalmic formulations

    Pharmaceutical excipients for ophthalmic formulations.

    This document is relevant to the following market areas

    Health Care - Derma
    Health Care - Pharma
    Health Care - Nutra
    Health Care - Animal Health
  • News Croda commits to Science Based Targets for reduction of greenhouse gas emissions

    Group aiming to achieve a 50% reduction in absolute GHG emissions based on 2006 levels by 2030 and an 80% reduction by 2050.
  • Video Supporting the World's Biggest Challenges

    Smart Science to Improve Lives. For more than 75 years Croda Denmark has been dedicated to safe and effective adjuvants for use in both human and veterinary vaccines, as well as blood fractioning processes. We offer an experienced passionate team and personal interaction with comprehensive on-site advice and support anywhere in the world.
  • Webinar Formulation solutions for cannabinoids

    The use of cannabinoids (CBD) is a growing marketplace dominated by oral and topical formulations. Croda offers Super Refined™ formulation solutions providing benefits such as; improving stability and reducing taste impact. Find out more here: